ArticleNutrients2024
Supplementation of Seaweed Extracts to the Diet Reduces Symptoms of Alzheimer's Disease in the APPswePS1ΔE9 Mouse Model.
Abstract read
In one paragraph
Article in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Holdfast-Derived Lipid Extract from the Patagonian MacroalgaPharmaceuticals (Basel, Switzerland) · 2026Article
- Marine Lipids and Alzheimer's Disease: Biochemistry, Bioaccessibility/Bioavailability, Metabolism, and Health Effects.Marine drugs · 2026Review
- Role of liver X receptors in the pathogenesis and treatment of chronic liver disease (Review).Molecular medicine reports · 2026Review
- Red Macroalgae as Sources of Antioxidant and Multifunctional Ingredients for Functional Foods: A Biorefinery Approach.Marine drugs · 2026Article
- Mechanisms, Mediators, and Pharmacological Approaches Targeting Brain Cholesterol Transport in Alzheimer's Disease.Current pharmaceutical design · 2026Review
- Therapeutic Potentials of the Seaweed-Derived Compounds for Alzheimer's Disease.Molecules (Basel, Switzerland) · 2025Review
- Therapeutic and Nutraceutical Potential ofMarine drugs · 2025Review
- Cholesterol-modifying strategies for Alzheimer disease: promise or fallacy?Expert review of neurotherapeutics · 2025Review
- Anti-atherosclerotic effects of natural compounds targeting lipid metabolism and inflammation: Focus on PPARs, LXRs, and PCSK9.Atherosclerosis plus · 2025Review
- The Advancements of Marine Natural Products in the Treatment of Alzheimer's Disease: A Study Based on Cell and Animal Experiments.Marine drugs · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Nikita MartensDepartment of Internal Medicine, Section Pharmacology and Vascular Medicine, Erasmus University Medical Center, 3015 GE Rotterdam, The Netherlands.ORCID 0000-0001-6382-3379
Na ZhanDepartment of Internal Medicine, Section Pharmacology and Vascular Medicine, Erasmus University Medical Center, 3015 GE Rotterdam, The Netherlands.
Sammie C YamDepartment of Internal Medicine, Section Pharmacology and Vascular Medicine, Erasmus University Medical Center, 3015 GE Rotterdam, The Netherlands.
Frank P J LeijtenDepartment of Internal Medicine, Section Pharmacology and Vascular Medicine, Erasmus University Medical Center, 3015 GE Rotterdam, The Netherlands.
Marcella PalumboDepartment of Food and Drug, University of Parma, 43124 Parma, Italy.
Martien CaspersDepartment of Microbiology and Systems Biology, The Netherlands Organization for Applied Scientific Research (TNO), 2333 BE Leiden, The Netherlands.ORCID 0000-0002-0248-4008
Assia TianeDepartment of Neuroscience, Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, B-3590 Hasselt, Belgium.ORCID 0000-0003-3931-8254
Silvia FriedrichsInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, D-53127 Bonn, Germany.
Yanlin LiDepartment of Internal Medicine, Section Pharmacology and Vascular Medicine, Erasmus University Medical Center, 3015 GE Rotterdam, The Netherlands.
Leonie van Vark-van der ZeeDepartment of Internal Medicine, Section Pharmacology and Vascular Medicine, Erasmus University Medical Center, 3015 GE Rotterdam, The Netherlands.ORCID 0009-0008-7660-3330
Gardi VoortmanDepartment of Internal Medicine, Section Pharmacology and Vascular Medicine, Erasmus University Medical Center, 3015 GE Rotterdam, The Netherlands.
Francesca ZimettiDepartment of Food and Drug, University of Parma, 43124 Parma, Italy.ORCID 0000-0002-6665-263X
Dick JaarsmaDepartment of Neuroscience, Erasmus University Medical Center, 3015 CN Rotterdam, The Netherlands.
Lars VerschurenDepartment of Microbiology and Systems Biology, The Netherlands Organization for Applied Scientific Research (TNO), 2333 BE Leiden, The Netherlands.ORCID 0000-0002-7847-9037
Johan W JonkerDepartment of Pediatrics, Section of Molecular Metabolism and Nutrition, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.ORCID 0000-0002-3919-5437
Folkert KuipersDepartment of Pediatrics, Section of Molecular Metabolism and Nutrition, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.ORCID 0000-0003-2518-737X
Dieter LütjohannInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, D-53127 Bonn, Germany.ORCID 0000-0002-7941-8308
Tim VanmierloDepartment of Internal Medicine, Section Pharmacology and Vascular Medicine, Erasmus University Medical Center, 3015 GE Rotterdam, The Netherlands.ORCID 0000-0003-2912-0578
Monique T MulderDepartment of Internal Medicine, Section Pharmacology and Vascular Medicine, Erasmus University Medical Center, 3015 GE Rotterdam, The Netherlands.
Funding
Alzheimer Forschung Initiative AFI-18024CBAlzheimer Forschung Initiative AFI-22034CBAlzheimer Nederland WE.03-2018-06 ANAlzheimer Nederland WE.03-2022-06Alzheimer Nederland WE.15-2021-08Dutch Research Council 16437Ministry of University and Research DN. 1553 11.10.2022
Abstract
We previously demonstrated that diet supplementation with seaweed
Indexed as
Alzheimer DiseaseDietary SupplementsDisease Models, AnimalSeaweedAmyloid beta-Protein PrecursorAnimalsCholesterolHippocampusHumansMaleMiceMice, TransgenicPlant ExtractsPlaque, AmyloidSargassumtau ProteinsAmyloid beta-Protein PrecursorCholesterolPlant Extractstau ProteinsAlzheimer’s diseasecholesterol metabolisminflammationliver X receptorsoxyphytosterolsseaweed
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.